CompletedNCT00242619
Rosiglitazone added to treatment for depression with insulin resistance
About this title
Read the official source — NCT00242619Medication studyAges 18–60United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- StanfordSee all locations and recruitment
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00242619
- Official title
Show the full official title
Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stanford
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stanford University, a university.
Did this study involve medication?
Yes. The study involved medication, including rosiglitazone.
Who was this study for?
Listed age limits: 18 years to 60 years.
